Wednesday, July 8, 2026

pharma · Anal Neoplasm · Lassa Fever · INO

INOVIO Pharmaceuticals

INOVIO Pharmaceuticals is a pharma organization headquartered in Plymouth Meeting, USA. It trades on NYSE under ticker INO. Primary therapeutic focus areas include Anal Neoplasm, Lassa Fever, Prostate Cancer, Chronic Hep

660 West Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, US HQ
203 Employees
Public company Type
INO · NYSE Ticker
Company details
Status
Public
HQ
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, US
Employees
203
Programs
46
Drugs
8
Patents
75
Clinical program

Medpulser Electroporation with Bleomycin

Phase 3 · other · Head Neck Cancer

Medpulser Electroporation with Bleomycin for Head Neck Cancer is a Phase 3 program (other) at INOVIO PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Internal code HNBE-03-02

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
INOVIO PHARMACEUTICALS, INC.
Phase
Phase 3
Modality
other
Indication
Head Neck Cancer
Status
terminated
Trials
1